Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy

Biomarkers

Volumn 15, Issue 3, 2010, Pages 243-248

  An, Xin ^a,b   Ding, Pei Rong ^a,b   Xiang, Xiao Juan ^a,b   Wang, Zhi Qiang ^a,b   Wang, Feng Hua ^a,b   Feng, Fen ^a,b   Jiang, Wen Qi ^a,b   He, You Jian ^a,b   Xu, Rui Hua ^a,b   Li, Yu Hong ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Carcinoembryonic antigen surge; Chemotherapy; Irinotecan; Metastatic colorectal cancer

Indexed keywords

CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); FEMALE; HISTOPATHOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; RETROSPECTIVE STUDY; SCREENING; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77951671589     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547500903477377     Document Type: Article

References (21)

1. Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J, Fakih M. (2006). Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 70:49-53.
2. Aquino A, Formica V, Prete SP, Correale PP, Massara MC, Turriziani M, De Vecchis L, Bonmassar E. (2004). Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res 49:383-396
3. Aquino A, Prete SP, Greiner JW, Giuliani A, Graziani G, Turriziani M, De Filippi R, Masci G, Bonmassar E, De Vecchis L. (1998). Efect of the combined treatment with 5-fuorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res 4:2473-2481
4. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. (1989). Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57: 327-334
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. (2004). Cetuximab monotherapy and cetuximab plus irinote-can in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
6. Fletcher RH. (1986). Carcinoembryonic antigen. Ann Intern Med 104:66-73.
7. Hanke B, Riedel C, Lampert S, Happich K, Martus P, Parsch H, Himmler B, Hohenberger W, Hahn EG, Wein A. (2001). CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative frst-line chemotherapy with weekly 24-hour infusion of high-dose 5-fuorouracil (5-FU) and folinic acid (FA). Ann Oncol 12:221-226
8. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Tun MJ. (2005). Cancer statistics, 2005. CA Cancer J Clin 55:10-30.
9. Li YH, An X, Xiang XJ, Wang ZQ, Wang FH, Feng F, Jiang WQ, He YJ, Xu RH. (2009). [Clinical signifcance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy.]. Ai Zheng 28:939-944
10. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfeld MR, Hayes DF, Bast RC Jr. (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327
11. Meyerhardt JA, Mayer RJ. (2005). Systemic therapy for colorectal cancer. N Engl J Med 352:476-487
12. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen C. (1993). An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. Jama 270:943-947
13. Ohtsukasa S, Okabe S, Yamashita H, Iwai T, Sugihara K. (2003). Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol 129:719-726
14. Prete SP, Turriziani M, Massara MC, De Rossi A, Correale P, De Vecchis L, Torino F, Bonmassar L, Aquino A. (2008). Combined efects of 5-fuorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res 27:5.
15. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as frst-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
16. Sorbye H, Dahl O. (2004). Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol 43:495-498
17. Terasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
18. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, De Gramont A. (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237
19. Trillet-Lenoir V, Chapuis F, Touzet S, Barbier JY, Freyer G, Gaudin JL, Lombard-Bohas C, Valette PJ, Lledo G, Gouttebel MC, Boyer JD, Chassignol L, Hamon H, Claudel-Bonvoisin S, Leprince E
20. Amoyal P, Glehen O, Darnand P, Heilmann M, O, Bleuse JP. (2004). Any clinical beneft from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol (R Coll Radiol) 16:196-203.
21. Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Yen CC, Chen WS, Jiang JK, Yang SH, Wang HS, Chen PM. (2002). Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer. Hepatogastroenterology 49: 388-392